Literature DB >> 12696986

Pharmaceutical care programmes for the elderly: economic issues.

Grainne E Crealey1, Ian K Sturgess, James C McElnay, Carmel M Hughes.   

Abstract

Pharmaceutical care is defined as the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life. It describes the process through which a pharmacist collaborates with a patient and with healthcare professionals in designing, implementing and monitoring a therapeutic plan that will produce specific, desirable therapeutic outcomes for the patient. The elderly are a patient population who could particularly benefit from pharmaceutical care provision as they are at greater risk of experiencing significant drug-related problems such as inappropriate prescribing, noncompliance with prescribed medication and adverse drug reactions/interactions leading to a decrease in health-related quality of life. The extent of economic benefit of pharmaceutical care reported in the literature is variable and its generalisability is suspect due to the lack of trials which have utilised a robust research design. The few studies which have undertaken a rigourous economic evaluation have used a range of data collection methods that is reflective of the difficulty of capturing essential data. Furthermore, even in well-designed studies, the generalisability of economic evaluations to other countries is questionable because of unique national data collection systems and an inability to pool international data because of disparities between different healthcare systems. The use of a suitable measure for health-related quality of life is also problematic in a very diverse and heterogeneous population such as the elderly and, therefore, adds to the difficulties of inclusion of such measures in economic analyses of pharmaceutical care programmes. A more standardised approach to data collection is required to facilitate economic analyses as an essential element in the evaluation of any pharmaceutical care programme for the elderly. Suggestions on such approaches, together with a critical appraisal of studies performed to date, are the focus of this review.

Entities:  

Mesh:

Year:  2003        PMID: 12696986     DOI: 10.2165/00019053-200321070-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  56 in total

1.  Factors influencing the detection rate of drug-related problems in community pharmacy.

Authors:  T Westerlund; A B Almarsdóttir; A Melander
Journal:  Pharm World Sci       Date:  1999-12

2.  Conducting at-home medication reviews.

Authors:  V Meade
Journal:  Am Pharm       Date:  1992-06

3.  Pharmaceutical care: will pharmacy incorporate its philosophy of practice?

Authors:  L M Posey
Journal:  J Am Pharm Assoc (Wash)       Date:  1997 Mar-Apr

4.  The physician and pharmacist team. An effective approach to cholesterol reduction.

Authors:  P E Bogden; L M Koontz; P Williamson; R D Abbott
Journal:  J Gen Intern Med       Date:  1997-03       Impact factor: 5.128

Review 5.  The Short-Form 36 (SF-36) Health Survey and its use in pharmacoeconomic evaluation.

Authors:  J Brazier
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

6.  The IMPROVE study: background and study design. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers.

Authors:  B L Carter; D C Malone; R J Valuck; D J Barnette; C D Sintek; S J Billups
Journal:  Am J Health Syst Pharm       Date:  1998-01-01       Impact factor: 2.637

7.  Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory-care clinic.

Authors:  N H Lobas; P W Lepinski; P W Abramowitz
Journal:  Am J Hosp Pharm       Date:  1992-07

8.  Pharmaceutical care for patients with skin diseases: a campaign year at Swedish pharmacies.

Authors:  B Hammarström; A Wessling; J L Nilsson
Journal:  J Clin Pharm Ther       Date:  1995-12       Impact factor: 2.512

9.  A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy.

Authors:  J T Hanlon; M Weinberger; G P Samsa; K E Schmader; K M Uttech; I K Lewis; P A Cowper; P B Landsman; H J Cohen; J R Feussner
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

Review 10.  Epidemiology of adverse drug reactions in the elderly by drug class.

Authors:  R J Beyth; R I Shorr
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 4.271

View more
  6 in total

1.  Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings.

Authors: 
Journal:  Br J Gen Pract       Date:  2010-01       Impact factor: 5.386

Review 2.  Pharmaceutical care, European developments in concepts, implementation, teaching, and research: a review.

Authors:  J W Foppe van Mil; Martin Schulz; Th F J Dick Tromp
Journal:  Pharm World Sci       Date:  2004-12

3.  Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.

Authors:  Francisco Jódar-Sánchez; Amaia Malet-Larrea; José J Martín; Leticia García-Mochón; M Puerto López Del Amo; Fernando Martínez-Martínez; Miguel A Gastelurrutia-Garralda; Victoria García-Cárdenas; Daniel Sabater-Hernández; Loreto Sáez-Benito; Shalom I Benrimoj
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

4.  Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings.

Authors: 
Journal:  Br J Gen Pract       Date:  2010-01       Impact factor: 5.386

5.  Economic evaluation of end stage renal disease patients undergoing hemodialysis.

Authors:  A Suja; R Anju; V Anju; J Neethu; P Peeyush; R Saraswathy
Journal:  J Pharm Bioallied Sci       Date:  2012-04

6.  Identifying Potential Drug-Related Problems Among Geriatric Patients With Use of an Integrated Clinical Decision Support Tool.

Authors:  Veera Bobrova; Daniela Fialová; Shane Desselle; Jyrki Heinämäki; Daisy Volmer
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.